Ocugen Förvaltning
Förvaltning kriterier kontrolleras 2/4
Ocugen VD är Shankar Musunuri, utsedd i Sep 2013, har en mandatperiod på 12.58 år. totala årliga ersättningen är $ 4.84M, bestående av 15.7% lön 84.3% bonusar, inklusive företagsaktier och optioner. äger direkt 0.73% av företagets aktier, värda $ 4.18M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2 år respektive 5.3 år.
Viktig information
Shankar Musunuri
Verkställande direktör
US$4.8m
Total ersättning
| VD-lön i procent | 15.65% |
| Anställning som VD | 12.6yrs |
| Ägande av VD | 0.7% |
| Ledningens genomsnittliga anställningstid | 2yrs |
| Styrelsens genomsnittliga mandatperiod | 5.3yrs |
Senaste uppdateringar av ledningen
Recent updates
OCGN: Retinal Gene Therapy Pipeline Will Drive Future Upside Potential
Narrative Update on Ocugen Analyst price targets for Ocugen have moved higher, with several recent increases of $3 to $7 tied to positive preliminary data for OCU410, expectations around OCU400 in retinitis pigmentosa, and a growing view of the company as an emerging player in gene therapy for blinding ocular disorders. Analyst Commentary Recent research coverage on Ocugen centers on its gene therapy pipeline and the implications for valuation if key clinical and regulatory milestones are met.OCGN: Late Stage Retinal Gene Therapies Will Drive Future Upside Potential
Ocugen's analyst price targets have moved higher by several dollars, with analysts pointing to Ocugen's Phase 3 OCU400 program, early OCU410 data and a perceived opportunity in retinal disease markets as key reasons for the updated views. Analyst Commentary Recent research coverage on Ocugen has leaned constructive, with several firms updating their models and price targets after new clinical data and program milestones.OCGN: Retinal Gene Therapy Milestones Will Drive Future Upside Potential
Ocugen's updated fair value estimate has shifted to $11.57 from $10.36 as analysts factor in a series of higher price targets on the stock, supported by recent positive clinical data and new coverage that highlights its gene therapy pipeline in retinal diseases. Analyst Commentary Recent research on Ocugen is clustered around its gene therapy portfolio in retinal diseases, with several firms updating models and targets after new data readouts and coverage initiations.OCGN: Late Stage Gene Therapy Progress Will Drive Future Upside Potential
Ocugen's analyst price target has moved higher toward $22, reflecting updated fair value estimates of about $10.36 per share and analyst focus on recent OCU410 Phase 2 data and OCU400's Phase 3 progress in blinding ocular disorders. Analyst Commentary Recent research on Ocugen centers on how the new OCU410 Phase 2 readout and the OCU400 Phase 3 program could influence valuation, risk, and execution over the next few years.Ocugen: Downgrading After OCU410 Data Release
Mar 09OCGN: Trial Progress And CFO Appointment Will Support Future Upside Potential
Narrative update on Ocugen Analysts have made a modest adjustment to their Ocugen price target, keeping fair value around $9.00. Small tweaks to the discount rate and future P/E assumptions refine, rather than overhaul, their view on the stock.OCGN: Positive Trial Data And New CFO Appointment Will Drive Upside
Ocugen's updated analyst price target edges higher, with a new fair value estimate of $9.00 per share supported by slightly adjusted assumptions for the discount rate, long term revenue growth, profit margin, and future P/E multiple. This indicates analysts are fine tuning their models rather than making a major shift in view.OCGN: Positive Trial Data And Capital Raise Will Drive Future Upside
Narrative Update The analyst price target for Ocugen has been fine tuned by a few cents, with only marginal shifts in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as analysts adjust their models in line with recent industry wide recalibrations seen in other coverage. Analyst Commentary Recent Street research on other companies in the broader building products and housing related space shows a mix of optimism on long term demand and caution around nearer term volatility.OCGN: Pipeline Milestones Will Drive Upside As Execution Risks Moderate
Analysts have trimmed their fair value estimate for Ocugen to $9.00. They link this move to slightly lower assumed discount rates and modest tweaks to long term revenue growth, profit margin, and future P/E expectations.OCGN: Pipeline Milestones Will Support Upside Despite Competitive And Capital Allocation Risks
Analysts have modestly trimmed their price target on Ocugen to around $9.00 per share. This reflects slightly lower discount rate and valuation assumptions as they factor in sustained but more competitively pressured growth and margins.OCGN: Exclusive Licensing Deal Will Drive Upside Amid Industry Headwinds
Ocugen's analyst price target remains steady at $9.00, as analysts cite ongoing competitive pressures and a lack of expected demand rebound in the sector as key factors for maintaining their current valuation outlook. Analyst Commentary Analyst sentiment around Ocugen reflects a balance of cautious optimism and ongoing concerns, shaped by sector-wide trends and company-specific challenges.OCGN: Upbeat Licensing Agreement Is Expected To Drive Shareholder Value In Coming Years
Narrative Update: Ocugen Analyst Price Target Revision Analysts have raised their price target for Ocugen from $8.20 to $9.00, citing increased revenue growth expectations and improved profit margin forecasts. Analyst Commentary Following the recent revision in Ocugen's price target, analysts have provided additional insight into the factors influencing their perspectives.OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
Ocugen's analyst price target remained steady at $8.20, as analysts see unchanged fair value amid stable growth projections and profitability outlooks, according to recent reviews. Analyst Commentary Recent Street research provides a mixed outlook for Ocugen, reflecting both positive momentum and ongoing challenges as analysts assess the company's valuation and prospects for future growth.Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target was reaffirmed at $8.20, as analysts cite stable revenue growth and profit margin projections, with only minor changes to discount rate and future P/E assumptions supporting their steady outlook. Analyst Commentary Street research highlights a range of perspectives surrounding Ocugen’s outlook, as analysts weigh factors that could either support or limit future upside in the company’s valuation and execution.Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target has been raised significantly from $6.48 to $8.20, reflecting growing optimism among analysts based on stronger projected revenue growth and improving profit margins. Analyst Commentary Recent price target revisions signal a shift in analysts' outlook on Ocugen, highlighting both enthusiasm and lingering concerns regarding the company’s path forward.
Gene Therapy Advances Will Unlock New Treatment Options
Advancing gene therapies for unmet needs may drive significant future revenue growth and market share if upcoming products secure approvals.Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | US$5m | US$758k | -US$68m |
| Sep 30 2025 | n/a | n/a | -US$64m |
| Jun 30 2025 | n/a | n/a | -US$57m |
| Mar 31 2025 | n/a | n/a | -US$58m |
| Dec 31 2024 | US$2m | US$758k | -US$54m |
| Sep 30 2024 | n/a | n/a | -US$51m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$5m | US$758k | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$79m |
| Jun 30 2023 | n/a | n/a | -US$90m |
| Mar 31 2023 | n/a | n/a | -US$86m |
| Dec 31 2022 | US$8m | US$715k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$74m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$69m |
| Dec 31 2021 | US$8m | US$541k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$500k | -US$34m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$572k | US$420k | -US$20m |
Ersättning vs marknad: Shankar s total kompensation ($USD 4.84M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 2.57M ).
Ersättning vs inkomst: Ersättningen för Shankar har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Shankar Musunuri (61 yo)
12.6yrs
Anställning
US$4,841,822
Kompensation
Dr. Shankar Musunuri, Ph D., MBA, is Co-Founder of OrthoCellix, Inc. and serves as its Chairman, Chief Executive Officer President and Secretary. Dr. Musunuri is the Co-Founder of Ocugen, Inc. since Septem...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 12.6yrs | US$4.84m | 0.73% $ 4.2m | |
| Co-founder & Independent Director | no data | US$211.25k | 0.21% $ 1.2m | |
| Chief Scientific Officer and Head of Research & Development | 3.6yrs | US$2.14m | 0.063% $ 360.3k | |
| Chief Medical Officer | 2.1yrs | US$2.89m | 0.0013% $ 7.5k | |
| Chief Financial Officer | less than a year | inga uppgifter | 0.15% $ 840.6k | |
| Executive Vice President of Operations | less than a year | inga uppgifter | inga uppgifter | |
| Chief Accounting Officer & Principal Accounting Officer | 1.5yrs | US$1.19m | 0.00053% $ 3.0k | |
| General Counsel | no data | inga uppgifter | inga uppgifter | |
| AVP & Head of Corporate Communications | no data | inga uppgifter | inga uppgifter | |
| Head of People & Culture | 2yrs | inga uppgifter | inga uppgifter | |
| Chief Development Officer | less than a year | US$1.31m | inga uppgifter | |
| VP & Head of Regulatory & Quality | 3.2yrs | inga uppgifter | inga uppgifter |
2.0yrs
Genomsnittlig anställningstid
57.5yo
Genomsnittlig ålder
Erfaren ledning: OCGN s ledningsgrupp anses vara erfaren ( 2 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 6.6yrs | US$4.84m | 0.73% $ 4.2m | |
| Co-founder & Independent Director | 6.6yrs | US$211.25k | 0.21% $ 1.2m | |
| Member of Retina Scientific Advisory Board | 6.4yrs | inga uppgifter | inga uppgifter | |
| Member of Retina Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Vaccine Scientific Advisory Board Member | 5.3yrs | inga uppgifter | inga uppgifter | |
| Vaccine Scientific Advisory Board Member | 5.3yrs | inga uppgifter | inga uppgifter | |
| Vaccine Scientific Advisory Board Member | 5.3yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 6.6yrs | US$196.25k | 0.40% $ 2.3m | |
| Independent Director | 6yrs | US$203.75k | 0.022% $ 126.0k | |
| Vaccine Scientific Advisory Board Member & Independent Director | less than a year | US$205.18k | inga uppgifter | |
| Vaccine Scientific Advisory Board Member | 5.3yrs | inga uppgifter | inga uppgifter | |
| Chair of Retina Scientific Advisory Board | 1.9yrs | inga uppgifter | inga uppgifter |
5.3yrs
Genomsnittlig anställningstid
61yo
Genomsnittlig ålder
Erfaren styrelse: OCGN s styrelse anses vara erfaren ( 5.3 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/30 09:49 |
| Aktiekurs vid dagens slut | 2026/04/30 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Ocugen, Inc. bevakas av 8 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |